Don Farthing, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10 - Hatfield CRC, Room 3-3288
- Bethesda, MD 20892
- 240-858-3651
- farthingde@mail.nih.gov
RESEARCH SUMMARY
Don Farthing heads the mass spectrometry and epitope discovery facility (MSEDF) that supports preclinical and clinical researchers from the Center for Immuno-Oncology. The facility has tandem mass spectrometers (UPLC-PDA-QTof, HS-GC-QqQ) that are utilized to support translational research (e.g., development of adoptive T cell therapies, graft- versus-host disease, deuterium imaging of rapidly proliferating cells).
US Patent and Trademark Office patent, US 11,684,306. Buxbaum, N.P. (lead inventor) et al, “Stable water isotope labeling and magnetic resonance imaging for visualization of rapidly dividing cells”, issued June 27, 2023.
https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/116843…
Areas of Expertise
Don Farthing, Ph.D.
Research
The MSEDF provides technical support for research involving GVHD and adoptive T cell immunotherapies. The facility provides expertise in using tandem mass spectrometry (MS) techniques to support translational preclinical/clinical research, and knowledge and experience in epitope discovery for use in the development of novel cancer immunotherapies.
Biography
Don Farthing, Ph.D.
Don Farthing received his Ph.D. in Pharmaceutical Sciences from the Medical College of VA. He utilizes sensitive bioanalytical techniques such as tandem HS-GC-MS/MS and UPLC-PDA-MS/MS to perform quantitative and qualitative analysis on samples (e.g., cell culture, blood, urine, other biospecimens) in support of pre-clinical and clinical research involving graft-versus-host disease (GVHD), other immunology related research, non-radioactive tumor imaging, and cancer immunotherapy.